Incretin pipeline pharmacology
Incretin pipeline pharmacology: 5 articles from Peptides Facts. Evidence-led reference on research peptides.
Amycretin: One Molecule, Two Receptor Families
Every unimolecular co-agonist before it combined receptors from the same structural family. Amycretin carries GLP-1 and amylin activity on a single chain, and those two receptors are not relatives. That is the design problem, and the source of everything the approach gains and gives up.
Amylin Receptor Agonists: Cagrilintide and a Second Satiety Pathway
Amylin is not an incretin. It is co-secreted with insulin, it enters the brain through a different door, and its receptor is a calcitonin receptor wearing an accessory protein. That separation from GLP-1 is the entire argument for the class.
GIP Agonism or GIP Antagonism: The Question the Field Has Not Settled
Two development programmes are pushing the same receptor in opposite directions, and both are producing weight loss in humans. That is not a paradox anyone has resolved. It is the largest open question in incretin pharmacology.
Oral GLP-1: Absorption Enhancers and the Bioavailability Problem
A 31-residue peptide swallowed into a protein-digestion system should not reach the circulation at all. One does, at roughly one percent, and only because an excipient rewrites the local chemistry of a few square millimetres of stomach lining for a few minutes.
Survodutide: Glucagon Receptor Agonism and the Liver Endpoint
Survodutide engages the glucagon receptor and the GLP-1 receptor, and nothing else. Stripping out the GIP arm makes it the cleanest available test of what glucagon agonism contributes on its own — and the liver is where that contribution should show first.